Search Results

Showing results 61-71 of 103 for 'Cancer'


  • pre-leukemic-stem-cells-tn
    Leukemia Cells are Addicted to a Healthy Gene

    Leukemia cells are able to stay alive, aggressively dividing, virtually forever… but how? New Weizmann research suggests that about 25 percent of the time, there is a ""balance of terror"" between the cancer-promoting gene and a second, normal version. This normal gene functions alongside the mutation, keeping the cells both cancerous and alive.

    /news-media/news-releases/leukemia-cells-are-addicted-to-a-healthy-gene
  • Israelis-give-a-double-punch-to-triple-negative-cancer-thumb
    Israelis Give a Double Punch to Triple-Negative Breast Cancer

    Triple negative breast cancer targets young black or Hispanic women and those of Jewish Ashkenazi descent, and standard therapies don't work for long. In a novel approach, Weizmann scientists engineered a two-front attack by binding different antibodies to different parts of growth receptors. A vaccination against cancer is their ultimate goal.

    /news-media/in-the-news/israelis-give-a-double-punch-to-triple-negative-breast-cancer
  • Time-to-rethink-chemotherapy-thumb
    Time to Rethink Chemotherapy?

    Israel21c reports on why chemo fails. The Weizmann Institute's research on the family trees of cells sheds light on cancer recurrence and ""will likely have profound implications for the way leukemia and other cancers are treated in the future.""

    /news-media/in-the-news/time-to-rethink-chemotherapy
  • Israeli-researchers-discovery-could-lead-to-new-type-of-cancer-treatment-thumb
  • group-of-t-cells-attack-tn
    T-cell Therapies for Cancer: From Outsider to Pharmaceutical Darling

    As Britain's Royal Pharmaceutical Society reports in its <em>Pharmaceutical Journal</em>, researchers working on T-cell therapies for cancer – such as Weizmann's Prof. Zelig Eshhar – were snubbed for years… until now. This thorough overview of the field's beginning – including in Prof. Eshhar's lab – and its future makes clear the importance of T cells.

    /news-media/in-the-news/t-cell-therapies-for-cancer-from-outsider-to-pharmaceutical-darling
  • US–Canadian-Fund-Looks-to-Israeli-Cancer-Researchers-for-Answers-thumb
  • safer-chemo-thanks-to-israeli-math-thumb
    Safer Chemo, Thanks to Israeli Math

    In a remarkable example of cross-disciplinary application, Weizmann Institute mathematicians and others developed a new model for evaluating infection risk for chemotherapy patients. The work could lead to a more individualized approach to cancer treatment.

    /news-media/in-the-news/safer-chemo-thanks-to-israeli-math
  • cancer-drugs-while-you-sleep-tn
    Why Cancer Drugs May Work Better While You Sleep

    <em>Time</em> reports on the recent finding by Weizmann scientists that our bodies fight cancer better during the day, meaning that nighttime might be much better for administering cancer drugs. This ""happy accident"" is an example of how basic research can shed light on important issues.

    /news-media/in-the-news/why-cancer-drugs-may-work-better-while-you-sleep
  • the-transformation-tn
    The Transformation

    Writing in The New Yorker, Dr. Jerome Groopman examines whether controlling cancer is a more viable option than trying to destroy it. A new treatment for the often-fatal acute myelogenous leukemia (AML) aims to do just that by forcing immature cells to grow up, rather than turn into leukemia cells – a breakthrough that builds on the work of Weizmann's Prof. Leo Sachs.

    /news-media/in-the-news/the-transformation